ELTX Elicio Therapeutics
- 8.980
- -0.020-0.22%
Elicio Therapeutics News
Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $10
Elicio Therapeutics to Present New Preliminary Data From the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients With MKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies
Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO Is the Most Bullish Insider, and Their Stock Value Gained 11%last Week
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data From the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Elicio Therapeutics today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research ("AACR") Annual Meeting, taking place in San Diego, California from April 5-10, 2024.
Express News | Oppenheimer Reiterates Perform on Elicio Therapeuticsto Perform
Elicio Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 — Oppenheimer Reiterates Perform → Perform 01/17/2024 68.97% HC Wainwright & Co. $10 → $11 Mai
Elicio Therapeutics 2023 Loss/Shr $6.96 >ELTX
Elicio Therapeutics 2023 Loss/Shr $6.96 >ELTX
Press Release: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates -- ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meetin
WIMI, TTNP and STI Among Mid-day Movers
Express News | Elicio Therapeutics Shares Are Trading Higher. The Company Announced a $6 Million Private Placement Financing to Purchase up to 1,032,702 Shares at $5.81 per Pre-funded Warrant
Canopy Growth, Outlook Therapeutics, Immuneering Among Healthcare Movers
Express News | Elicio Therapeutics Announces $6.0M Private Placement Financing To Purchase Up To 1,032,702 Shares At $5.81 Per Pre-Funded Warrant
Press Release: Elicio Therapeutics Announces $6.0 Million Private Placement Financing
Elicio Therapeutics Announces $6.0 Million Private Placement Financing BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinic
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Titan Pharma (NASDAQ:TTNP) stock moved
OGEN, SSP and ZENV Among Mid-day Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSocietal CDMO (NASDAQ:SCTL) shares moved upwards by 23.4% to $0.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $59.7 million. Apollomics (NASDAQ:AP
Analysis
Price Target
No Data
